A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.
Angiotensin-Converting Enzyme 2
Betacoronavirus
Bradykinin
/ analogs & derivatives
Bradykinin B2 Receptor Antagonists
/ pharmacology
COVID-19
Compassionate Use Trials
Coronavirus Infections
/ complications
Dyspnea
/ etiology
Feedback, Physiological
/ drug effects
Humans
Inflammation
Models, Biological
Off-Label Use
Pandemics
Peptidyl-Dipeptidase A
/ physiology
Pneumonia, Viral
/ complications
Receptors, Bradykinin
/ drug effects
Receptors, Virus
/ physiology
SARS-CoV-2
COVID-19 Drug Treatment
bradykinin
bradykinin receptor
coronavirus
icatibant
inflammation
injury
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
20
04
2020
accepted:
22
04
2020
pubmed:
3
5
2020
medline:
1
7
2020
entrez:
3
5
2020
Statut:
ppublish
Résumé
As of April 20, 2020, over time, the COVID-19 pandemic has resulted in 157 970 deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%. With the pandemic rapidly spreading, and health delivery systems being overwhelmed, it is imperative that safe and effective pharmacotherapeutic strategies are rapidly explored to improve survival. In this paper, we use established and emerging evidence to propose a testable hypothesis that, a vicious positive feedback loop of des-Arg(9)-bradykinin- and bradykinin-mediated inflammation → injury → inflammation, likely precipitates life threatening respiratory complications in COVID-19. Through our hypothesis, we make the prediction that the FDA-approved molecule, icatibant, might be able to interrupt this feedback loop and, thereby, improve the clinical outcomes. This hypothesis could lead to basic, translational, and clinical studies aimed at reducing COVID-19 morbidity and mortality.
Identifiants
pubmed: 32359101
doi: 10.1096/fj.202000967
pmc: PMC7267506
doi:
Substances chimiques
Bradykinin B2 Receptor Antagonists
0
Receptors, Bradykinin
0
Receptors, Virus
0
bradykinin, des-Arg(9)-
15958-92-6
icatibant
7PG89G35Q7
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Bradykinin
S8TIM42R2W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7265-7269Subventions
Organisme : Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University (EACPHS, WSU)
Pays : International
Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
Shock. 2016 Sep;46(3):239-48
pubmed: 27082314
J Pharmacol Exp Ther. 2002 Oct;303(1):232-7
pubmed: 12235256
Acta Physiol Scand. 1997 Mar;159(3):189-98
pubmed: 9079149
Eur J Pharmacol. 1997 Jul 16;331(1):31-8
pubmed: 9274927
Am J Physiol Renal Physiol. 2004 May;286(5):F875-80
pubmed: 15075183
Kidney Int. 1992 Oct;42(4):1020-9
pubmed: 1453578
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Int Forum Allergy Rhinol. 2020 Jul;10(7):806-813
pubmed: 32279441
Allergy. 2011 Jan;66(1):149-54
pubmed: 20649895
Front Immunol. 2019 Aug 27;10:2046
pubmed: 31507620
J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):610-615
pubmed: 28483314
Br J Clin Pharmacol. 1999 Dec;48(6):861-5
pubmed: 10594491
Hypertens Res. 2010 Aug;33(8):772-7
pubmed: 20505673
Virology. 2008 Feb 5;371(1):32-43
pubmed: 17961624
N Engl J Med. 2015 Jan 29;372(5):418-25
pubmed: 25629740
Emerg Med Pract. 2020 May 01;22(5):1-28
pubmed: 32207910
West J Emerg Med. 2020 Apr 10;21(3):507-509
pubmed: 32302282
J Pharmacol Sci. 2005 Sep;99(1):6-38
pubmed: 16177542
Clin Exp Allergy. 2013 Apr;43(4):475-82
pubmed: 23517043
J Allergy Clin Immunol. 1996 Aug;98(2):283-7
pubmed: 8757204
Respir Res. 2019 Jun 6;20(1):110
pubmed: 31170972
J Hum Hypertens. 1989 Jun;3 Suppl 1:169-76
pubmed: 2778791
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Clin Cosmet Investig Dermatol. 2011;4:61-8
pubmed: 21760740
Pharmacol Rev. 2005 Mar;57(1):27-77
pubmed: 15734727
Rhinology. 2020 Jun 1;58(3):299-301
pubmed: 32240279
Allergy. 2017 Jun;72(6):994-998
pubmed: 27926986
Arch Pathol Lab Med. 2014 Feb;138(2):266-9
pubmed: 23782136
Kidney Int. 2006 Nov;70(10):1823-31
pubmed: 17003818
JAMA. 2020 Feb 7;:
pubmed: 32031570
Br J Pharmacol. 2002 Sep;137(2):276-84
pubmed: 12208785
Curr Opin Pharmacol. 2009 Apr;9(2):125-31
pubmed: 19124274
Br J Pharmacol. 1992 Nov;107(3):653-9
pubmed: 1335332
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32173725
Diseases. 2016 Jul 25;4(3):
pubmed: 28933406
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 01;314(1):L17-L31
pubmed: 28935640
Clin Pharmacol Ther. 1996 Jul;60(1):8-13
pubmed: 8689816
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Virol. 2009 Mar;83(5):2298-309
pubmed: 19109397
Pharmacogenet Genomics. 2010 Sep;20(9):532-6
pubmed: 20625347
JAMA. 2020 Apr 15;:
pubmed: 32293639
Expert Opin Pharmacother. 2012 Oct;13(15):2233-47
pubmed: 22970904
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
FASEB J. 2020 Jun;34(6):7265-7269
pubmed: 32359101
J Allergy Clin Immunol. 2001 Jan;107(1):105-13
pubmed: 11149999
Eur J Pharmacol. 1992 Jan 14;210(2):115-20
pubmed: 1601053
J Infect Dis. 2016 Feb 15;213(4):532-40
pubmed: 26310310
Front Microbiol. 2014 Jun 17;5:296
pubmed: 24987391
Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37
pubmed: 22123383